Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleBasic Science Investigations

Theranostics of Malignant Melanoma with 64CuCl2

Chunxia Qin, Hongguang Liu, Kai Chen, Xiang Hu, Xiaowei Ma, Xiaoli Lan, Yongxue Zhang and Zhen Cheng
Journal of Nuclear Medicine May 2014, 55 (5) 812-817; DOI: https://doi.org/10.2967/jnumed.113.133850
Chunxia Qin
1Molecular Imaging Program at Stanford (MIPS), Canary Center at Stanford for Cancer Early Detection, Department of Radiology and Bio-X Program, Stanford University, Stanford, California; and
2Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei Province Key Laboratory of Molecular Imaging, Wuhan, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hongguang Liu
1Molecular Imaging Program at Stanford (MIPS), Canary Center at Stanford for Cancer Early Detection, Department of Radiology and Bio-X Program, Stanford University, Stanford, California; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kai Chen
1Molecular Imaging Program at Stanford (MIPS), Canary Center at Stanford for Cancer Early Detection, Department of Radiology and Bio-X Program, Stanford University, Stanford, California; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiang Hu
1Molecular Imaging Program at Stanford (MIPS), Canary Center at Stanford for Cancer Early Detection, Department of Radiology and Bio-X Program, Stanford University, Stanford, California; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaowei Ma
1Molecular Imaging Program at Stanford (MIPS), Canary Center at Stanford for Cancer Early Detection, Department of Radiology and Bio-X Program, Stanford University, Stanford, California; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaoli Lan
2Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei Province Key Laboratory of Molecular Imaging, Wuhan, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yongxue Zhang
2Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei Province Key Laboratory of Molecular Imaging, Wuhan, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhen Cheng
1Molecular Imaging Program at Stanford (MIPS), Canary Center at Stanford for Cancer Early Detection, Department of Radiology and Bio-X Program, Stanford University, Stanford, California; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    (A) Western blots of CTR1 in 12 cancer cell lines. (B) Quantitative analysis of Western blot results. (C) Western blots of CTR1 in B16F10 and A375M tumor tissues. (D) B16F10 and A375M’s cellular uptake of 64CuCl2 at 0.5, 1, 2, and 4 h time points and blocking studies (excess cold CuCl2 was added) at each time point. (E) Efflux of 64CuCl2 from A375M and B16F10 cells at 0.5, 1, 2, 4, and 16 h after 2 h incubation with 64CuCl2.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    (A) Decay-corrected whole-body coronal small-animal PET images of C57BL/6 mice bearing B16F10 murine melanoma tumors (upper) and athymic nude mice bearing A375M human melanoma (lower) from 5-min static scans at 1, 2, 4, 24, 48, and 72 h after intravenous injection of 64CuCl2. Tumors are indicated by arrows. (B and C) Small-animal PET quantification of tumors and major organs, including liver, kidney, and muscle, at 1, 2, 4, 24, 48, and 72 h after intravenous injection of 64CuCl2 in B16F10 (B) and A375M (C) tumor–bearing mice, respectively (n = 4).

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    Time–activity curves of tumor and major organs of C57BL/6 mice bearing B16F10 murine melanoma tumors from 35-min dynamic scans after intravenous injection of 64CuCl2 (3 MBq [∼80 μCi]/mouse, n = 4).

  • FIGURE 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4.

    (A–C) Kaplan–Meier plot of time-to-sacrifice for therapy group (dotted line) and control group (solid line). (A) Group of mice inoculated with 1 million B16F10 cells. (B) Group of mice inoculated with 2 million B16F10 cells. (C) Group of A375M tumor models. Time is expressed in days from therapy. (D) Representative images of A375M tumor necrosis after 64CuCl2 treatment (left, control mouse; right, treated mouse).

  • FIGURE 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 5.

    H&E staining of livers and kidneys from therapy group and control group.

Tables

  • Figures
  • Additional Files
    • View popup
    TABLE 1

    Biodistribution Results of 64CuCl2 in B16F10 and A375M Tumor-Bearing Mice (n = 4)

    OrganB16F10A375M
    Blood1.51 ± 0.191.94 ± 0.56
    Heart5.16 ± 0.738.85 ± 0.65
    Lungs6.64 ± 0.4810.17 ± 1.58
    Liver14.06 ± 2.3313.37 ± 1.32
    Spleen3.46 ± 0.424.59 ± 0.10
    Pancreas2.74 ± 0.363.48 ± 0.61
    Stomach3.92 ± 0.826.47 ± 0.86
    Brain0.88 ± 0.091.00 ± 0.07
    Intestine4.35 ± 0.996.82 ± 0.40
    Kidneys11.86 ± 0.5610.34 ± 0.53
    Skin1.18 ± 0.511.95 ± 0.36
    Muscle1.03 ± 0.181.13 ± 0.36
    Bone1.66 ± 0.241.82 ± 0.24
    Tumor4.14 ± 0.243.59 ± 0.36
    Uptake ratio
     Tumor to blood2.79 ± 0.421.94 ± 0.44
     Tumor to lung0.63 ± 0.070.36 ± 0.04
     Tumor to liver0.30 ± 0.040.26 ± 0.04
     Tumor to muscle4.11 ± 0.073.46 ± 1.25
    • Data are presented as percentage injected dose per gram (%ID/g) ± SD.

Additional Files

  • Figures
  • Tables
  • Supplemental Data

    Files in this Data Supplement:

    • Supplemental Data
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 55 (5)
Journal of Nuclear Medicine
Vol. 55, Issue 5
May 1, 2014
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Theranostics of Malignant Melanoma with 64CuCl2
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Theranostics of Malignant Melanoma with 64CuCl2
Chunxia Qin, Hongguang Liu, Kai Chen, Xiang Hu, Xiaowei Ma, Xiaoli Lan, Yongxue Zhang, Zhen Cheng
Journal of Nuclear Medicine May 2014, 55 (5) 812-817; DOI: 10.2967/jnumed.113.133850

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Theranostics of Malignant Melanoma with 64CuCl2
Chunxia Qin, Hongguang Liu, Kai Chen, Xiang Hu, Xiaowei Ma, Xiaoli Lan, Yongxue Zhang, Zhen Cheng
Journal of Nuclear Medicine May 2014, 55 (5) 812-817; DOI: 10.2967/jnumed.113.133850
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Insights into Trace Metal Metabolism in Health and Disease from PET: "PET Metallomics"
  • Monte Carlo N-Particle (MCNP) Modeling of the Cellular Dosimetry of 64Cu: Comparison with MIRDcell S Values and Implications for Studies of Its Cytotoxic Effects
  • Detection of Increased 64Cu Uptake by Human Copper Transporter 1 Gene Overexpression Using PET with 64CuCl2 in Human Breast Cancer Xenograft Model
  • Google Scholar

More in this TOC Section

  • PET/MRI of Hypoxic Atherosclerosis Using 64Cu-ATSM in a Rabbit Model
  • Tumor Uptake of Anti-CD20 Fabs Depends on Tumor Perfusion
  • How Sensitive Is the Upper Gastrointestinal Tract to 90Y Radioembolization? A Histologic and Dosimetric Analysis in a Porcine Model
Show more Basic Science Investigations

Similar Articles

Keywords

  • melanoma
  • copper transporter 1
  • 64CuCl2
  • PET
  • radionuclide therapy
SNMMI

© 2025 SNMMI

Powered by HighWire